Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors NCT02867592 Adrenal Cortica...
Alveolar Soft P...
Central Nervous...
Childhood Clear...
Clear Cell Sarc...
Ewing Sarcoma
Hepatoblastoma
Hepatocellular ...
Osteosarcoma
Recurrent Adren...
Recurrent Alveo...
Recurrent Clear...
Recurrent Ewing...
Recurrent Hepat...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Malig...
Recurrent Osteo...
Recurrent Prima...
Recurrent Renal...
Recurrent Rhabd...
Recurrent Soft ...
Recurrent Thyro...
Refractory Adre...
Refractory Alve...
Refractory Clea...
Refractory Ewin...
Refractory Hepa...
Refractory Hepa...
Refractory Mali...
Refractory Oste...
Refractory Prim...
Refractory Prim...
Refractory Rena...
Refractory Rhab...
Refractory Soft...
Refractory Thyr...
Refractory Wilm...
Renal Cell Carc...
Rhabdomyosarcom...
Soft Tissue Sar...
Solid Neoplasm
Thyroid Gland M...
Wilms Tumor
Cabozantinib
Cabozantinib S-...
Pharmacological...
2 Years - 30 Years National Cancer Institute (NCI) View Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) NCT03526250 Advanced Malign...
Recurrent Child...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Laboratory Biom...
Palbociclib
Pharmacological...
12 Months - 21 Years National Cancer Institute (NCI) View Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) NCT03698994 Advanced Malign...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Prim...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Wilms Tumor
Pharmacokinetic...
Ulixertinib
12 Months - 21 Years National Cancer Institute (NCI) View Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma NCT02452554 Pleuropulmonary...
Recurrent Malig...
Recurrent Neuro...
Recurrent Rhabd...
Recurrent Synov...
Wilms Tumor
Laboratory Biom...
Lorvotuzumab Me...
Pharmacological...
12 Months - 30 Years Children's Oncology Group View Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients NCT04213794 Malignant Abdom...
Malignant Pelvi...
Recurrent Colon...
Recurrent Desmo...
Recurrent Fallo...
Recurrent Gastr...
Recurrent Lipos...
Recurrent Malig...
Recurrent Ovari...
Recurrent Prima...
Recurrent Recta...
Recurrent Rhabd...
Recurrent Sarco...
Refractory Colo...
Refractory Desm...
Refractory Fall...
Refractory Gast...
Refractory Lipo...
Refractory Mali...
Refractory Ovar...
Refractory Prim...
Refractory Rect...
Refractory Rhab...
Refractory Sarc...
Resectable Lipo...
Resectable Mali...
Resectable Sarc...
Cisplatin
Cytoreductive S...
Doxorubicin
Hyperthermic In...
Sodium Thiosulf...
Computed Tomogr...
Magnetic Resona...
Positron Emissi...
Biospecimen Col...
1 Year - 25 Years Mayo Clinic View Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial NCT04284774 Malignant Solid...
Recurrent Adren...
Recurrent Ectom...
Recurrent Epend...
Recurrent Ewing...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Melan...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Recurrent Thyro...
Recurrent WHO G...
Refractory Adre...
Refractory Epen...
Refractory Ewin...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Mela...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Refractory Thyr...
Refractory WHO ...
Biospecimen Col...
Bone Marrow Asp...
Computed Tomogr...
Magnetic Resona...
Positron Emissi...
Radionuclide Im...
Tipifarnib
12 Months - 21 Years National Cancer Institute (NCI) View Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) NCT03213678 Advanced Malign...
Ann Arbor Stage...
Ann Arbor Stage...
Malignant Gliom...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Neur...
Refractory Non-...
Refractory Prim...
Rhabdoid Tumor
Stage III Osteo...
Stage III Soft ...
Stage IV Osteos...
Stage IV Soft T...
Stage IVA Osteo...
Stage IVB Osteo...
Wilms Tumor
Biospecimen Col...
Computed Tomogr...
FDG-Positron Em...
Magnetic Resona...
Samotolisib
X-Ray Imaging
12 Months - 21 Years National Cancer Institute (NCI) View Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial NCT04320888 Hematopoietic a...
Recurrent Epend...
Recurrent Ewing...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Lymph...
Recurrent Malig...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Recurrent WHO G...
Refractory Epen...
Refractory Ewin...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Lymp...
Refractory Mali...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Refractory WHO ...
Wilms Tumor
Computed Tomogr...
Magnetic Resona...
Positron Emissi...
Radionuclide Im...
Selpercatinib
X-Ray Imaging
12 Months - 21 Years National Cancer Institute (NCI) View Trabectedin and Irinotecan for Refractory Pediatric Sarcomas NCT02509234 Recurrent Child...
Recurrent Ewing...
Recurrent Rhabd...
Combined chemot...
10 Years - 40 Years Technical University of Munich View Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) NCT03698994 Advanced Malign...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Prim...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Wilms Tumor
Pharmacokinetic...
Ulixertinib
12 Months - 21 Years National Cancer Institute (NCI) View Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma NCT04299113 Rhabdomyosarcom...
Vinorelbine
Mocetinostat
13 Years - Jonsson Comprehensive Cancer Center View Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 Central Nervous...
Central Nervous...
Central Nervous...
Embryonal Tumor...
Pineoblastoma
Primary Central...
Recurrent Child...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Rhabd...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Rhab...
Adavosertib
Irinotecan Hydr...
1 Year - 21 Years National Cancer Institute (NCI) View Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients NCT04213794 Malignant Abdom...
Malignant Pelvi...
Recurrent Colon...
Recurrent Desmo...
Recurrent Fallo...
Recurrent Gastr...
Recurrent Lipos...
Recurrent Malig...
Recurrent Ovari...
Recurrent Prima...
Recurrent Recta...
Recurrent Rhabd...
Recurrent Sarco...
Refractory Colo...
Refractory Desm...
Refractory Fall...
Refractory Gast...
Refractory Lipo...
Refractory Mali...
Refractory Ovar...
Refractory Prim...
Refractory Rect...
Refractory Rhab...
Refractory Sarc...
Resectable Lipo...
Resectable Mali...
Resectable Sarc...
Cisplatin
Cytoreductive S...
Doxorubicin
Hyperthermic In...
Sodium Thiosulf...
Computed Tomogr...
Magnetic Resona...
Positron Emissi...
Biospecimen Col...
1 Year - 25 Years Mayo Clinic View Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma NCT04299113 Rhabdomyosarcom...
Vinorelbine
Mocetinostat
13 Years - Jonsson Comprehensive Cancer Center View Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702 Recurrent Solid...
Recurrent Ewing...
Recurrent Hepat...
Recurrent Malig...
Recurrent Malig...
Recurrent Neuro...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Recurrent Wilms...
Refractory Ewin...
Refractory Hepa...
Refractory Mali...
Refractory Mali...
Refractory Neur...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Onivyde
Talazoparib
Temozolomide
12 Months - 30 Years St. Jude Children's Research Hospital View Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) NCT03526250 Advanced Malign...
Recurrent Child...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Laboratory Biom...
Palbociclib
Pharmacological...
12 Months - 21 Years National Cancer Institute (NCI) View